Dr. Robert Arch, Ph.D. (Cancer immunology) has over 30 years of academic and industry experience with deep expertise of drug development in oncology, immunologic disorders, and chronic liver diseases in large pharma and small biotech companies. His expertise includes directing R&D, managing global operations, and serving as CEO of a Nasdaq-listed company. His broad clinical development and regulatory experiences encompass R&D stages from IND to early Phase III.

As CEO of OncoSec Medical Incorporated, he crafted and executed a streamlined strategy for the company’s proprietary TAVO™-EP program, which resulted in FDA endorsement for a new clinical path forward. At Elpiscience, he transformed R&D culture and successfully advanced two assets into clinical development.

Dr. Arch has driven the advancement of more than 20 first-in-class and best-in-disease assets from pre-clinical stages to clinical proof of concept and beyond, while contributing to the development of Target Product Profiles (TPPs) of more than ten assets for market differentiation and sales projections in the US, Europe, and Asia.

He has a demonstrated track record of securing more than $50 million in funding and has cultivated a global network of relationships with scientists, clinicians, and thought leaders.